Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Valve-in-Valve: High or Low Implantation for Better Outcomes?

Original Title: Transcatheter Replacement of Failed Bioprosthetic Valve. Large Multicenter Assessment of the Effect of Implantation Depth on Hemodynamics after Aortic Valve-in Valve.

Reference: Matheus Simonato, et al. Circ. Cardiovasc. Interv 2016;9:e003651

 

Courtesy of Dr. Carlos Fava.

 

valve_in_valveAt present, most patients undergoing surgical valve replacement receive a bioprosthetic valve, which lasts from 10 to 15 years. However, when it starts failing, reoperation is a high risk.

Transcatheter valve implantation inside a failed surgical bioprosthetic valve (V-in-V) could eventually solve this problem, but its evolution and exact implantation depth continues to raise questions.

The study analyzed 292 high risk consecutive patients form the International V-in-V (VIVID) registry.

The purpose of this study was to determine optimal implantation depth for the best hemodynamic outcome, defined as <20 mmHg gradient.

Mean age was 78.9 years with more than 90% patients with symptomatic dyspnea in FC III-IV. Bioprosthetic valves had failed approximately 10 after procedure, caused by:

  • stenosis, 40%
  • mixed factors, 35%
  • regurgitation, 25%

From the total number of patients, 157 received the CoreValve and 135 the Sapiens XT.

High implantation depth was associated to lower rates of post implantation elevated gradients compared to low implantation depth, and this was true for both valves:

CoreValve Evolut

  • High implantation depth 15%
  • Low implantation depth 34.2%

p=0.03

Sapiens XT

  • High implantation 18.5%
  • Low implantation 43.5%

p=0.03

Implantation depth was a strong predictor of post implantation gradient.

 

Conclusion

High implantation, both for CoreValve and Sapiens XT ─ inside a failed surgical valve ─ is a strong independent predictor of satisfactory hemodynamic outcomes.

 

Editorial Comment

V-in-V is a significantly less invasive strategy that solves stenosis or failure of bioprosthetic surgical valves.

To meet its increasing demand and optimize results requires that we master this implantation technique.

 

Courtesy of Dr. Carlos Fava. Favaloro Foundation, Buenos Aires, Argentina.

 

We value your opinion. You are more than welcome to leave your comments, thoughts, question or any ideas here below.

More articles by this author

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

TAVI in TAVI: Clinical and Hemodynamic Outcomes According to the Type of Prosthesis Used in TAVI-in-TAVI

With the expansion of TAVI to younger and lower surgical risk patients, bioprosthetic valve degeneration and the need for repeat interventions are expected to...

Percutaneous Closure of Patent Foramen Ovale in Patients Over 60 Years Old With Cryptogenic Stroke: A Safe and Effective Strategy?

Cryptogenic stroke accounts for up to one-third of all ischemic strokes and remains strongly associated with the presence of a patent foramen ovale (PFO),...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...